Avandamet licensed for use in triple therapy

The fixed dose glitazone/biguanide combination Avandamet (rosiglitazone plus metformin) is now licensed for use in triple therapy with a sulphonylurea for patients with type II diabetes, particularly those who are overweight, who have not achieved sufficient glycaemic control with maximally tolerated doses of metformin and a sulphonylurea.

Patients currently receiving dual therapy comprising metformin and a sulphonylurea, or triple therapy comprising rosiglitazone, metformin and a sulphonylurea given individually may be transferred to an appropriate strength of Avandamet to substitute for the dose of metformin or of rosiglitazone and metformin currently being used.

Patients receiving triple therapy are at increased risk of developing fluid retention, heart failure and hypoglycaemia. Such patients should therefore be monitored and Avandamet discontinued if heart failure develops or the dose of sulphonylurea reduced if hypoglycaemia develops.

Further information: GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Tel: (0800) 221441.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more